期刊
AMERICAN JOURNAL OF THE MEDICAL SCIENCES
卷 348, 期 4, 页码 306-314出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MAJ.0b013e3182a5b6dd
关键词
Renin; Angiotensinogen; Kidney; Renin inhibition; Intrarenal angiotensin II
资金
- Novartis Pharmaceuticals Corporation [CSPP100AUSNC06]
- Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [1P30GM103337]
The development of glomerulonephritis causes glomerular injury and renal dysfunction and is thought to increase renin release, thus activating the renin-angiotensin system (RAS). The aims of this study were to demonstrate activation of the intrarenal RAS and determine the effects of direct renin inhibition (DRI) on the progression of glomerulonephritis. Rats were treated with anti-Thy1.1 antibody with or without DRI, aliskiren (30 mg/kg/d). In the glomerulonephritic rats, protein, microalbumin excretion levels, urinary angiotensinogen excretion, glomerular expansion score and intrarenal transforming growth factor-beta and plasminogen activator inhibitor-1 mRNA levels were augmented compared with control rats; however, hypertension was not observed in the glomerulonephritic rats, and aliskiren treatment did not modify their blood pressure. The increases in urinary protein (94.7 +/- 13.0 mg/d) and microalbumin (7.52 +/- 2.6 mg/d) excretion were reduced by aliskiren (43.6 +/- 4.5 mg/d of protein and 2.57 +/- 0.7 mg/d of microalbumin). Furthermore, the progression of glomerular expansion and elevation of intrarenal transforming growth factor-b and plasminogen activator inhibitor-1 levels were prevented by aliskiren. Importantly, aliskiren suppressed the augmentation of urinary angiotensinogen levels, the increased angiotensinogen expression in the kidneys and the increases in Ang II levels in renal medulla induced by the anti-Thy1.1 antibody. These results suggest that DRI with aliskiren prevents intrarenal RAS activation leading to mitigation of the development of glomerulonephritis. In addition, the renoprotective effects of DRI on glomerulonephritis occur in a blood pressure-independent manner. Accordingly, treatment with aliskiren may be an effective approach to treat glomerulonephritis and other intrarenal RAS-associated kidney diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据